Liver Transplant Unit, Austin Health, Studley Road, Heidelberg, VIC 3084, Australia.
Gut. 2011 Feb;60(2):247-54. doi: 10.1136/gut.2010.223206. Epub 2010 Oct 29.
To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV).
A prospective open-label study of TDF 300 mg daily. Patients receiving combination ADV/LAM prior to baseline were switched to TDF/LAM.
Multiple tertiary referral centres.
Sixty patients were enrolled. The median age was 48.5 years (range 21e80), 46 (77%) were male and 40 (67%) were HBeAg positive. Thirty-eight patients (63%) were switched from ADV to TDF, the remainder from ADV/LAM to TDF/LAM. At baseline, substitutions conferring resistance to LAM or ADV were present in 20 patients (33%) and 17 patients (28%), respectively. The median baseline viral load was 5.33 log₁₀ IU/ml (range 2.81-8.04). Patients initially treated with TDF monotherapy with persistent viral replication at or after 24 weeks were switched to TDF/LAM. The main outcome measures were change in HBV viral load from baseline and percentage of patients achieving an undetectable viral load (<15 IU/ml).
Results are reported at 96 weeks of treatment. One patient discontinued TDF at 10 days due to rash. The time-weighted change in viral load from baseline to week 12 was -2.19 log10 IU/ml overall. The median change in HBV DNA from baseline to weeks 12, 24, 48 and 96 was -2.86, -3.23, -3.75 and -4.03 log₁₀ IU/ml, respectively. At 48 and 96 weeks, 27/59 (46%) and 38/59 (64%) patients achieved a HBV DNA <15 IU/ml. The response was independent of baseline LAM therapy or mutations conferring ADV resistance.
In heavily pretreated patients with a high rate of genotypic resistance, TDF retains significant activity against HBV although this appears diminished in comparison with studies of naïve patients.
评估替诺福韦酯(TDF)在先前拉米夫定(LAM)治疗失败且存在显著病毒复制(HBeAg 阳性者 HBV DNA >10⁵ 拷贝/ml,HBeAg 阴性者 HBV DNA >10⁴ 拷贝/ml)的慢性乙型肝炎病毒(HBV)感染成人患者中的疗效,这些患者在接受阿德福韦酯(ADV)至少 24 周治疗后仍有病毒复制。
一项替诺福韦酯 300mg 每日治疗的前瞻性开放标签研究。基线时接受 ADV/LAM 联合治疗的患者转换为 TDF/LAM。
多个三级转诊中心。
共纳入 60 例患者。中位年龄为 48.5 岁(范围 21-80),46 例(77%)为男性,40 例(67%)为 HBeAg 阳性。38 例(63%)患者从 ADV 转换为 TDF,其余患者从 ADV/LAM 转换为 TDF/LAM。基线时,20 例(33%)和 17 例(28%)患者存在对 LAM 或 ADV 耐药的替代突变。中位基线病毒载量为 5.33log₁₀IU/ml(范围 2.81-8.04)。初始接受 TDF 单药治疗且治疗 24 周后仍有病毒复制的患者转换为 TDF/LAM。主要观察指标为从基线开始的 HBV 病毒载量变化和达到病毒载量不可检测(<15IU/ml)的患者比例。
治疗 96 周时报告结果。1 例患者因皮疹在 10 天内停用 TDF。从基线到第 12 周时病毒载量的时间加权变化总体为-2.19log10IU/ml。从基线到第 12、24、48 和 96 周时 HBV DNA 的中位变化分别为-2.86、-3.23、-3.75 和-4.03log₁₀IU/ml。在第 48 和 96 周时,分别有 27/59(46%)和 38/59(64%)患者的 HBV DNA <15IU/ml。该反应与基线 LAM 治疗或 ADV 耐药相关突变无关。
在大量预先治疗且基因型耐药率较高的患者中,TDF 对 HBV 仍具有显著活性,但与初治患者的研究相比,这种活性似乎减弱。